Market Reports Center

Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2017


Report Details

Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2017

SKU DIFEB161701
Category Life Sciences
Publisher DelveInsight
Pages 224
Published Feb-17
Request Discount Pay by Wire/Invoice

Description

Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2017” emphasizes on the currently active CAR-T cell products in research and development. The Report covers the 35+ companies which are active in this field including 14 leading companies with 35 products targeting 20 different antigens and 9 different technologies. The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, Collaborations details and Deal values, Technologies and Targeted antigens. The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis. Report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are major concerns in the market for the usage of CAR-T cells.

Report Highlights:
• CAR-T cell Therapy Pipeline scenario
• Collaborations & partnering deals
• Current Prominent Research Areas and Key Players
• Pipeline product profiles CAR-T Technologies and Targeted Antigens
• Licensing opportunities
• Market Drivers and Barriers

Scope
• Overview of the global CAR-T cell therapy pipeline scenario, products and associated companies information
• Coverage of global CAR-T cell therapies under development
• Competitive landscape of products for key players and related indications
• Coverage of licensors, collaborators and Development partners, deal terms and deal values estimation
• Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
• Highlights of licensing & collaboration opportunities and funding details
• Highlights of latest CAR-T technologies and innovative companies
• Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis

Key Topics;
• CAR-T cell Therapy Pipeline scenario
• Current Prominent Research Areas and Key Players
• Collaborations details and Deal values
• Technologies and Targeted antigens
• Pipeline product profiles CAR-T Technologies and Targeted Antigens
• Licensing opportunities
• Market Drivers and Barriers
• SWOT Analysis


News/Press Release

Table of Content

1 Report Introduction
2 Executive Summary Snapshot
3 Executive Summary
4 Introduction
4.1. Chimeric antigen receptor (CAR) T-cells
4.2. History
4.3. CARs and Generations
4.4. Advantages of CAR-T cells
4.5. Adverse Events with CAR T-cell Therapy
5 Car-T Cell Therapy-Analysis
5.1. CAR-T Collaboration Deals
5.1.1. CAR-T Cells Therapy Collaborations and Deal Year
5.1.2. Collaborations & Deal Value Trends
5.1.3. Companies collaborations for future developments
5.2. CAR-T Acquisitions Deals
5.2.1. CAR-T Cells Therapy Acquisitions Trends
5.2.2. CAR-T Cells Therapy Acquisitions Offerings by Big Giants
5.3. New facility for the development of CAR-T cells
5.4. CAR-T Licensing Opportunities
5.5. Pipeline Scenario
5.5.1. Pipeline Products under Development-An Overview
5.5.2. Pipeline Products under Development by Company
5.5.3. CAR T-cells Therapeutic Areas & Companies
5.5.4. CAR-T cells Targeted Antigens
5.5.5. CAR-T Therapies-Clinical trials & Completion Year
5.5.6. CAR T-cell Technologies & Companies Involved
5.5.7. CAR-T Safety Switches & Company involved
6 Pipeline Profiles
7 Market Drivers
8 Market Barriers
9 SWOT Analysis
10 Report Methodology
11 Consulting Services

List of Figures

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 4: Companies CAR-T Investment for future developments, 2017
Table 5: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 6: Companies open for licensing and collaborations, 2017
Table 7: Number of Products under Development, 2017
Table 8: Number of Products under Development by Companies, 2017
Table 9: Number of Products under Development by Indication, 2017
Table 10: Number of Products Targeting CD19 Antigen, 2017
Table 11: Number of Products Targeting Other Antigens, 2017
Table 12: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 13: CAR T-cell Companies and Technologies, 2017
Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and future Profits (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Market Reports Center © Copyright 2017 All rights reserved.

wire transfer
ssl